Skip to main content
NSE - SMEListed
Invicta Diagnostic Limited Logo

Invicta Diagnostic Limited IPO

Invicta Diagnostic Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 100.00 (+17.65%)

Invicta Diagnostic Limited's completed its IPO journey with a successful listing on NSE on 08-12-2025. The public offering mobilized 33,08,800 Shares in total capital, comprising 33,08,800 Shares in fresh equity.

The offering was conducted within the price band of ₹80 to ₹85, with minimum application lots of 1600 shares. Investor participation during the 01-12-2025 to 03-12-2025 subscription window determined the final allocation pattern.

The basis of allotment was announced on 04-12-2025, finalizing share distribution to successful applicants. The listing represents a significant corporate development, providing the company with enhanced visibility and access to public capital markets.

Invicta Diagnostic IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Invicta Diagnostic IPO Key Performance Indicator
Company Financials ( In Crores )

Invicta Diagnostic IPO About Company

Incorporated in January 2021, Invicta Diagnostic Limited (operating as PC Diagnostics) is a Mumbai-based diagnostic services provider offering integrated radiology and pathology solutions through a hub-and-spoke model spread across the Mumbai Metropolitan Region, comprising a flagship advanced diagnostic hub in Thane West, three additional hubs in Bhayandar, Byculla, and Marol, and four spokes focused on basic imaging and sample collection; the company provides around 60 routine and 487 specialised pathology tests along with 96 basic and 130 advanced radiology tests, supported by a strong home-collection network and a team of 5 laboratory doctors, 20 radiologists, 127 technical staff, and 105 permanent employees as of May 31, 2025.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Invicta Diagnostic IPO Strength Factors

  1. Expanding Footprint Across Mumbai Metropolitan Region : Rapid growth from one centre in 2021 to seven multi-format diagnostic facilities (hubs, spokes, and a central lab) enhances accessibility and strengthens market presence.
  2. Comprehensive & Affordable Diagnostic Services : A one-stop offering of pathology and radiology solutions delivers convenience, faster diagnostics, and cost-effective care for patients under the “PC Diagnostics” brand.
  3. Advanced Technology & Skilled Medical Team : Modern imaging infrastructure including CT, MRI, and PET CT systems supported by experienced radiologists ensures accurate, high-quality, and efficient diagnostic outcomes.

Invicta Diagnostic IPO Risk Factors

  1. High Sensitivity to Brand Image & Patient Experience : Heavy reliance on walk-in customers means even small lapses in service quality, test accuracy, or turnaround time can damage reputation and impact revenue growth.
  2. Operational Dependence on Flagship Thane Centre : Centralized processing of majority tests at one key facility exposes the business to major disruptions in case of equipment failure, regulatory issues, or unforeseen events.
  3. Geographic Concentration Risk in MMR : Entire revenue comes from the Mumbai Metropolitan Region, making performance highly vulnerable to regional economic, policy, or healthcare disruptions.

Invicta Diagnostic IPO Lead Manager(s)

  • Socradamus Capital Private Limited

Invicta Diagnostic IPO Promoter(s)

  1. Dr. Ketan Jayantilal Jain
  2. Dr. Sanket Vinod Jain
  3. Rohit Prakash Srivastava
  4. Badal Kailash Naredi
  5. Jayesh Prakash Jain

Invicta Diagnostic IPO Company Details

Invicta Diagnostic Limited
Phone:
address:

Invicta Diagnostic IPO Registrar

Bigshare Services Private Limited
Name:
Phone:

Invicta Diagnostic IPO FAQs